Laura Alder, Medical Oncology Deputy Director at Duke Center for Brain and Spine Metastasis, shared a post on LinkedIn:
“Thrilled to share that our abstract, ‘Intracranial Efficacy and Treatment Beyond CNS Progression with Tarlatamab in Small Cell Lung Cancer : A Multi-Institutional Real-World Analysis‘ has been accepted for an oral presentation at the 2026 SNO/ASCO CNS Metastases Conference in Boston this August!
Brain metastases remain a major challenge in small cell lung cancer, and real-world data on tarlatamab’s intracranial activity are critically needed. Grateful to our multi-institutional team of collaborators for making this work possible.
Looking forward to sharing our findings at the Westin Copley Place, August 13-15. See you in Boston!”
Other articles featuring Laura Alder on OncoDaily.